SRPT Logo

Sarepta Therapeutics, Inc. (SRPT) 

NASDAQ$98.37
Market Cap
$9.55B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
72 of 925
Rank in Industry
51 of 528

SRPT Insider Trading Activity

SRPT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$4,955,728113
Sells
$11,061,140787

Related Transactions

Chambers Michael Andrewdirector1$4.96M0$0$4.96M
Boor Kathryn Jeandirector0$01$205,400$-205,400
Murray DallanChief Customer Officer0$01$508,900$-508,900
Estepan Ian MichaelChief Financial Officer0$01$822,100$-822,100
Wigzell Hans Lennart Rudolfdirector0$01$1.31M$-1.31M
Arif BilalChief Tech Ops Officer0$02$1.92M$-1.92M
Brown Ryan EdwardEVP, General Counsel0$01$6.3M$-6.3M

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 â€¦

Insider Activity of Sarepta Therapeutics, Inc.

Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $4.96M and sold $11.06M worth of Sarepta Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $6.22M and sold $11.71M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Chambers Michael Andrew (director) — $4.96M.

The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.

List of Insider Buy and Sell Transactions, Sarepta Therapeutics, Inc.

2024-12-12SaleWigzell Hans Lennart Rudolfdirector
10,500
0.011%
$124.84$1.31M-6.99%
2024-12-05SaleBoor Kathryn Jeandirector
1,636
0.0017%
$125.55$205,400-7.51%
2024-08-30SaleEstepan Ian MichaelChief Financial Officer
5,985
0.0063%
$137.36$822,100-10.44%
2024-08-16PurchaseChambers Michael Andrewdirector
37,038
0.0404%
$133.80$4.96M-7.99%
2024-06-25SaleArif BilalChief Tech Ops Officer
3,898
0.0043%
$163.23$636,271-20.99%
2024-06-25SaleBrown Ryan EdwardEVP, General Counsel
38,957
0.0421%
$161.61$6.3M-20.99%
2024-06-24SaleArif BilalChief Tech Ops Officer
7,859
0.0083%
$163.08$1.28M-23.74%
2024-05-02SaleMurray DallanChief Customer Officer
3,635
0.0041%
$140.00$508,900-4.30%
2024-03-11SaleBoor Kathryn Jeandirector
761
0.0008%
$122.93$93,550+3.09%
2024-03-08SaleWigzell Hans Lennart Rudolfdirector
15,000
0.0159%
$123.25$1.85M+0.78%
2024-03-05SaleMayo Stephendirector
3,135
0.0033%
$122.96$385,480+2.03%
2024-03-01SaleEstepan Ian MichaelChief Financial Officer
1,200
0.0013%
$128.30$153,960-2.59%
2024-03-01SaleBrown Ryan EdwardEVP, General Counsel
2,000
0.0021%
$125.34$250,680-2.59%
2024-03-01SaleArif BilalChief Tech Ops Officer
2,000
0.0021%
$128.84$257,676-2.59%
2023-11-03PurchaseINGRAM DOUGLAS SPresident & CEO
25,225
0.0275%
$79.36$2M+60.46%
2023-11-03PurchaseBarry Richarddirector
50,000
0.0542%
$78.81$3.94M+60.46%
2023-08-14PurchaseChambers Michael Andrewdirector
9,979
0.0104%
$109.47$1.09M+7.99%
2023-08-11PurchaseChambers Michael Andrewdirector
23,686
0.0254%
$108.05$2.56M+12.24%
2023-08-10PurchaseChambers Michael Andrewdirector
34,867
0.0374%
$106.15$3.7M+14.36%
2023-08-04SaleWigzell Hans Lennart Rudolfdirector
15,000
0.0163%
$106.72$1.6M+14.59%
Total: 152
*Gray background shows transactions not older than one year

Insider Historical Profitability

17.85%
Chambers Michael Andrewdirector
284034
0.2927%
$27.94M50+11.57%
HAYWOOD GEORGE WEAVER
8213717
8.4649%
$807.98M160<0.0001%
INGRAM DOUGLAS SPresident & CEO
390307
0.4022%
$38.39M70+25.87%
Barry Richarddirector
140000
0.1443%
$13.77M73+30.38%
BEHRENS M KATHLEENdirector
130517
0.1345%
$12.84M62+42.52%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$961,890,236
276
22.46%
$13.1B
$211,610,344
91
38.45%
$7.13B
$2,765,836
72
20.00%
$13.47B
$108,876,545
67
72.81%
$7.52B
Sarepta Therapeutics, Inc.
(SRPT)
$42,463,802
57
17.85%
$9.55B

SRPT Institutional Investors: Active Positions

Increased Positions235+45.19%10M+11.11%
Decreased Positions223-42.88%7M-8.46%
New Positions74New3MNew
Sold Out Positions60Sold Out2MSold Out
Total Postitions532+2.31%89M+2.65%

SRPT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$1.19M11.66%11.19M+168,672+1.53%2024-12-31
Vanguard Group Inc$969,872.009.46%9.09M+117,904+1.31%2024-12-31
Capital International Investors$928,419.009.06%8.7M+2M+38.95%2024-12-31
Janus Henderson Group Plc$462,048.004.51%4.33M-30,188-0.69%2024-12-31
State Street Corp$434,458.004.24%4.07M-200,902-4.7%2024-12-31
Farallon Capital Management Llc$305,849.002.98%2.87M+285,100+11.05%2024-12-31
Avoro Capital Advisors Llc$272,805.002.66%2.56M00%2024-12-31
Bank Of New York Mellon Corp$229,030.002.24%2.15M+26,581+1.25%2024-12-31
Wellington Management Group Llp$220,841.002.16%2.07M-657,842-24.13%2024-12-31
Jpmorgan Chase & Co$215,699.002.11%2.02M-178,279-8.11%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.